NKGen Biotech (NKGN) Price & Analysis

Q: What was NKGen Biotech’s price range in the past 12 months?

NKGen Biotech lowest stock price was $0.00 and its highest was $0.96 in the past 12 months.

Q: What is NKGen Biotech’s market cap?

NKGen Biotech’s market cap is $4.60M.

Q: When is NKGen Biotech’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is NKGen Biotech overvalued?

According to Wall Street analysts NKGen Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does NKGen Biotech pay dividends?

NKGen Biotech does not currently pay dividends.

Q: What is NKGen Biotech’s EPS estimate?

NKGen Biotech’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does NKGen Biotech have?

NKGen Biotech has 124,376,730 shares outstanding.

Q: Which hedge fund is a major shareholder of NKGen Biotech?

Currently, no hedge funds are holding shares in NKGN

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

117 Followers

NKGN Stock Chart & Stats

$0.05

$0.02(4.11%)

At close: Jan 08 4:00 PM EST

$0.05

$0.02(4.11%)

Day’s Range― - ―

52-Week Range$0.00 - $0.96

Previous CloseN/A

Volume116.73K

Average Volume (3M)5.29K

Market Cap

$4.60M

Enterprise ValueN/A

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-1.27

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.29

Shares Outstanding124,376,730

10 Day Avg. Volume5,077

30 Day Avg. Volume5,291

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

NKGen Biotech News

NKGen Biotech issues statement on NKGen Korea board appointments

NKGen Korea, formerly NKMax Co., recently completed a shareholder-approved name change on November 21, 2025. On this date,...

17d ago

NKGN

Nkgen Biotech’s Promising Alzheimer’s Study: A Potential Game-Changer?

Nkgen Biotech Inc. (($NKGN)) announced an update on their ongoing clinical study. Nkgen Biotech Inc. (NKGN) is conducting...

2M ago

NKGN

NKGen Biotech provides clarification on quotation display, trading status

NKGen Biotech (NKGN) issued the following statement in response to recent shareholder inquiries regarding its current trading status...

2M ago

NKGN

NKGen Biotech Announces Consulting Agreement with Dr. Kim

An announcement from NKGen Biotech ( ($NKGN) ) is now available. On September 25, 2025, NKGen Biotech, Inc....

3M ago

NKGN

NKGen Biotech Secures $2.5M in Stock Purchase Agreement

NKGen Biotech ( ($NKGN) ) has shared an update. On September 18, 2025, NKGen Biotech, Inc. entered into...

3M ago

NKGN

NKGen Biotech Acquires Majority Stake in NKMax

NKGen Biotech ( ($NKGN) ) has provided an announcement. On September 4, 2025, NKGen Biotech completed the acquisition...

3M ago

NKGN

NKGen Biotech announces completion of NKMax acquisition

NKGen Biotech (NKGN) announced the successful completion of its acquisition of a majority equity stake in NKMax, a...

3M ago

NKGN

NKGen Biotech presents troculeucel mechanism of action

NKGen Biotech (NKGN) announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel in Alzheimer’s Disease...

5M ago

NKGN

NKGen Biotech announces FDA granted EAP authorization for IND of troculeucel

NKGen Biotech (NKGN) announced that the U.S. Food and Drug Administration, FDA, has granted Expanded Access Program, EAP,...

5M ago

NKGN

NKGen Biotech Partners with HekaBio for SNK01 in Japan

NKGen Biotech ( ($NKGN) ) has issued an update. On July 14, 2025, NKGen Biotech entered into a...

5M ago

NKGN

NKGen Biotech, HekaBio enter strategic partnership to bring troculeucel to Japan

NKGen Biotech (NKGN) and HekaBio announced a strategic partnership to accelerate the regulatory, manufacturing and commercial development of...

5M ago

NKGN

NKGen Biotech Secures Funding Amid Compliance Challenges

NKGen Biotech ( ($NKGN) ) has shared an update. On July 14, 2025, NKGen Biotech entered into a...

5M ago

NKGN

NKGen Biotech announces expansion of Phase 1/2a troculeucel trial

NKGen Biotech (NKGN) announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial...

6M ago

NKGN

NKGen Biotech Approved as Preferred Bidder for NKMAX

NKGen Biotech ( ($NKGN) ) has shared an announcement. NKGen Biotech, Inc. has been approved by the Seoul...

6M ago

NKGN

NKGN FAQ

What was NKGen Biotech’s price range in the past 12 months?

NKGen Biotech lowest stock price was $0.00 and its highest was $0.96 in the past 12 months.

What is NKGen Biotech’s market cap?

NKGen Biotech’s market cap is $4.60M.

When is NKGen Biotech’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were NKGen Biotech’s earnings last quarter?

Currently, no data Available

Is NKGen Biotech overvalued?

According to Wall Street analysts NKGen Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NKGen Biotech pay dividends?

NKGen Biotech does not currently pay dividends.

What is NKGen Biotech’s EPS estimate?

NKGen Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NKGen Biotech have?

NKGen Biotech has 124,376,730 shares outstanding.

What happened to NKGen Biotech’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of NKGen Biotech?

Currently, no hedge funds are holding shares in NKGN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NKGen Biotech

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.